A study of BBO-11818 in combination with BBO-10203
Latest Information Update: 15 Feb 2026
At a glance
- Drugs BBO 11818 (Primary) ; BBO 8520 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 15 Feb 2026 New trial record
- 07 Jan 2026 According to a BridgeBio Oncology Therapeutics media release, combination studies of BBO-11818 with BBO-10203 are expected to open later in 2026.